A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
Safety and Immune Response of Influenza and Respiratory Vaccines in Adults
Study Overview
The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus / parainfluenza virus type 3 vaccine in healthy participants 18 to 49 years of age. A lipid nanoparticle will be used in this study.
Overall, the study is designed to:
- Assess the safety profile of the candidate formulations
- Describe the immunogenicity profile of the candidate formulations
- Eligible participants will be randomized to receive a single intramuscular injection of either one of the vaccine formulations.
Participants will be provided with a diary to solicit reporting of injection site reactions and systemic reactions, unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest AESIs).
Participants will also be required to record their daily temperature on the diary.
Study Details
The duration of study participation will be approximately 6 months for each participant.
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination, Human Metapneumovirus Vaccination
-
Age: 18 years - 49 years
-
Gender: All
Inclusion Criteria:
- Aged 18 to 49 years on the day of inclusion
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
- Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR
- Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.
Exclusion Criteria:
- Any medical condition or circumstance which, in the opinion of the investigator, might interfere with the evaluation of the study objectives
Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
This study investigates the safety and immunogenicity of vaccines for influenza, respiratory syncytial virus, human metapneumovirus, and parainfluenza in adults aged 18 to 49. Immunogenicity refers to the ability of a vaccine to provoke an immune response. The study uses hemagglutinin formulations in a trivalent influenza vaccine or a combined vaccine for the other viruses. A lipid nanoparticle, which is a tiny particle used to deliver the vaccine, will be used.
Participants will receive a single intramuscular injection of one of the vaccine formulations. They will keep a diary to report any injection site reactions, systemic reactions, and any adverse events. They will also record their daily temperature in the diary. This will help researchers gather important data on the safety and immune response of the vaccines.
- Who can participate: Healthy adults aged 18 to 49 years who meet specific criteria can participate. Female participants must not be pregnant, breastfeeding, and should use effective contraception or abstain from sex during the study.
- Study details: Participants will receive a single injection of a vaccine formulation and will need to maintain a diary to report any reactions or adverse events. They will also record their daily temperature.
- Study timelines: The study will last approximately 6 months.
Find a study site near you
,
Send a message
Enter your contact details to connect with study team
Primary Contact
